Tax-withholding share sale by Solid Biosciences (SLDB) director reported

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ilan Ganot reported a small net sale of shares mainly tied to restricted stock unit vesting and tax withholding.

An entity associated with his wife sold 2,658 shares of common stock in an open-market transaction at a weighted average price of $5.8233 per share, with individual trades ranging from $5.23 to $6.14. According to the disclosure, this sale was made to cover withholding taxes after previously granted restricted stock units vested and followed a durable automatic sales instruction adopted by Ms. Ganot, so it was not a discretionary trade.

On the same date, 4,861 restricted stock units held by Ms. Ganot converted into an equal number of common shares at no exercise price, reflecting the one-for-one RSU-to-share ratio. After these transactions, Mr. Ganot’s reported holdings include shares held individually, jointly with his spouse, and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		4,861	A	(1)	30,132	I	Wife
Common Stock	02/18/2026		S(3)		2,658(3)	D	$5.8233(4)	27,474	I	Wife
Common Stock								99,297	D(2)
Common Stock								19,394	I	See Footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			4,861	(6)	(6)	Common Stock	4,861	$0.00	9,722	I	Wife

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

3. This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

5. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

6. On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

	/s/ David Tyronne Howton as attorney-in-fact for Ilan Ganot	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Solid Biosciences (SLDB) director Ilan Ganot report?

He reported a small net sale linked to tax withholding and RSU vesting. An account associated with his wife sold 2,658 common shares, while 4,861 restricted stock units converted into an equal number of common shares at no exercise price.

How many Solid Biosciences (SLDB) shares were sold and at what price?

An entity associated with the director’s wife sold 2,658 common shares. The weighted average sale price was $5.8233 per share, with individual trades executed in a range between $5.23 and $6.14 per share, according to the disclosure.

Was the Solid Biosciences (SLDB) share sale by the Ganot family discretionary?

The sale was described as non-discretionary. It was executed under a durable automatic sales instruction adopted by Ms. Ganot to cover withholding taxes after restricted stock units vested, meaning it followed a pre-established sell-to-cover election rather than an active trading decision.

What happened to the restricted stock units in the Solid Biosciences (SLDB) Form 4?

4,861 restricted stock units held by Ms. Ganot were converted into 4,861 common shares at a $0.00 exercise price. The filing notes that each restricted stock unit converts into one share of common stock, reflecting a straightforward one-for-one conversion ratio.

What longer-term equity award to Ms. Ganot is referenced for Solid Biosciences (SLDB)?

The disclosure states that on February 13, 2024, Ms. Ganot was granted 19,444 restricted stock units. These units vest in four equal installments on each anniversary of the grant date, creating a four-year vesting schedule for the full award.

How are some of Ilan Ganot’s Solid Biosciences (SLDB) shares held indirectly?

The filing reports 19,394 shares held by Adam and Annie Ganot, and their successors, as trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017. Additional shares are reported as held by or with his wife through indirect ownership arrangements.